Muscular dystrophies are genetic disorders causing progressive muscle weakness and degeneration. Duchenne muscular dystrophy (DMD), the most common severe form in boys, affects the dystrophin protein essential for muscle integrity. Other types (Becker, limb-girdle, myotonic) vary in severity and age of onset. Treatment aims to slow progression and preserve function.
Corticosteroids (deflazacort, prednisone) slow DMD progression by 2–5 years when started early; daily dosing with careful monitoring for side effects. Gene therapy and exon-skipping antisense drugs (eteplirsen, golodirsen, viltolarsen for DMD) promote production of shortened but functional dystrophin; administered IV or IV infusion periodically. Physical therapy, stretching, and exercise maintain range of motion and muscle function. Orthotic devices, mobility aids, and wheelchairs support independence. Cardiac and respiratory monitoring prevents complications; ACE inhibitors and beta-blockers protect the heart from dystrophin loss.
Herbal supplements, creatine monohydrate, and CoQ10 are explored; evidence is minimal. Alternative medicine cannot replace steroid or gene-targeted therapy.
Stem cell therapy—autologous myogenic precursor cells and mesenchymal stem cells—has been studied for decades with limited clinical success. Gene therapy (microdystrophin vectors, base editing) represents a more promising regenerative approach. Myostatin inhibitors are under investigation. Clinical stem cell treatments marketed for muscular dystrophy often lack rigorous evidence and should not delay approved therapies.
| Option | Type | Evidence | Indicative cost | Invasiveness | Recovery |
|---|---|---|---|---|---|
| Deflazacort (Corticosteroid) | Standard | Strong | €150–250/month | Low | Daily; slows progression 2–5 years; long-term side effects require monitoring |
| Eteplirsen (Exondys 51) | Standard | Moderate | €300,000–500,000/year | Low | Weekly IV infusions; modest slowing of decline; disease stabilisation in some |
| Golodirsen (Vyondys 53) | Standard | Moderate | €350,000–550,000/year | Low | Weekly IV infusions; exon 53 skipping; slows decline |
| Gene Therapy (AAV Vector Microdystrophin) | Standard | Moderate | €1,200,000–2,000,000 | Medium | Single IV infusion; months to peak effect; durable; limited by AAV capacity |
| Physiotherapy & Stretching | Standard | Strong | €60–100/session | Low | Ongoing; prevents contractures; maintains function |
| Cardiac & Respiratory Monitoring | Standard | Strong | €200–400/visit | Low | Regular echocardiograms and spirometry; early intervention prevents crisis |
| Autologous Myogenic Stem Cell Transplantation | Regenerative | Limited | €25,000–50,000 | High | 6+ weeks; variable results; should not delay approved therapies |
| Mobility Aids & Orthotic Devices | Standard | Strong | €1,000–8,000 | Low | Immediate; independence extended |
No cure exists. Corticosteroids and exon-skipping drugs slow progression—often by 2–5 years—but do not stop or reverse muscle loss. Gene therapy shows promise for durable benefit; long-term outcomes are still being assessed.
Stem cell therapy has not proven effective in muscular dystrophy clinically. Gene therapy and exon-skipping antisense drugs are more promising because they target the genetic defect directly. Regenerative cell therapies remain investigational.
Very important. Corticosteroids, exon-skipping drugs, and gene therapy are most effective when started as early as possible—before significant muscle loss occurs. Delays result in lost opportunity for maximum benefit.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Educational overview of treatment options; not medical advice. Standard treatments reflect mainstream guidance; regenerative/stem-cell uses are largely investigational. Reviewed by the StemCellAtlas editorial team.
GMP-сертифицированная регенеративная медицина в сердце ЕС — от €3 000–8 000, доля от цен США или Германии. Индивидуальные протоколы для пациентов из 50+ стран.
Бесплатная оценка врача